These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 8429008)
1. Inhibition of dysthrombins Quick I and II by heparin cofactor II and antithrombin. Phillips JE; Shirk RA; Whinna HC; Henriksen RA; Church FC J Biol Chem; 1993 Feb; 268(5):3321-7. PubMed ID: 8429008 [TBL] [Abstract][Full Text] [Related]
2. Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor. Whinna HC; Church FC J Protein Chem; 1993 Dec; 12(6):677-88. PubMed ID: 8136018 [TBL] [Abstract][Full Text] [Related]
3. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. Becker DL; Fredenburgh JC; Stafford AR; Weitz JI J Biol Chem; 1999 Mar; 274(10):6226-33. PubMed ID: 10037709 [TBL] [Abstract][Full Text] [Related]
4. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity. Sheehan JP; Wu Q; Tollefsen DM; Sadler JE J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040 [TBL] [Abstract][Full Text] [Related]
5. Role of thrombin exosites in inhibition by heparin cofactor II. Rogers SJ; Pratt CW; Whinna HC; Church FC J Biol Chem; 1992 Feb; 267(6):3613-7. PubMed ID: 1740413 [TBL] [Abstract][Full Text] [Related]
6. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans. Sheehan JP; Tollefsen DM; Sadler JE J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495 [TBL] [Abstract][Full Text] [Related]
7. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. Holland CA; Henry AT; Whinna HC; Church FC FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II. Cooper ST; Rezaie AR; Esmon CT; Church FC Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592 [TBL] [Abstract][Full Text] [Related]
9. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. Van Deerlin VM; Tollefsen DM J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083 [TBL] [Abstract][Full Text] [Related]
10. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Bray B; Lane DA; Freyssinet JM; Pejler G; Lindahl U Biochem J; 1989 Aug; 262(1):225-32. PubMed ID: 2818566 [TBL] [Abstract][Full Text] [Related]
11. General features of the heparin-binding serpins antithrombin, heparin cofactor II and protein C inhibitor. Pratt CW; Church FC Blood Coagul Fibrinolysis; 1993 Jun; 4(3):479-90. PubMed ID: 8392392 [TBL] [Abstract][Full Text] [Related]
12. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition. Mitchell JW; Church FC J Biol Chem; 2002 May; 277(22):19823-30. PubMed ID: 11856753 [TBL] [Abstract][Full Text] [Related]
13. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition. Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357 [TBL] [Abstract][Full Text] [Related]
14. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. Church FC; Meade JB; Treanor RE; Whinna HC J Biol Chem; 1989 Feb; 264(6):3618-23. PubMed ID: 2914965 [TBL] [Abstract][Full Text] [Related]
15. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. Griffith MJ; Noyes CM; Church FC J Biol Chem; 1985 Feb; 260(4):2218-25. PubMed ID: 3838304 [TBL] [Abstract][Full Text] [Related]
16. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. Blinder MA; Tollefsen DM J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620 [TBL] [Abstract][Full Text] [Related]
17. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. Jeter ML; Ly LV; Fortenberry YM; Whinna HC; White RR; Rusconi CP; Sullenger BA; Church FC FEBS Lett; 2004 Jun; 568(1-3):10-4. PubMed ID: 15196911 [TBL] [Abstract][Full Text] [Related]
18. Molecular mapping of the thrombin-heparin cofactor II complex. Fortenberry YM; Whinna HC; Gentry HR; Myles T; Leung LL; Church FC J Biol Chem; 2004 Oct; 279(41):43237-44. PubMed ID: 15292227 [TBL] [Abstract][Full Text] [Related]
19. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. Derechin VM; Blinder MA; Tollefsen DM J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of heparin cofactor II anticoagulant activity. Bauman SJ; Church FC J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]